Search research articles
Contact Us
Filters
Showing results (91-100 of 122) with videos related to
Page
of 13
Sort By:
British Journal of Cancer
|
March 27, 2024
Extending the dosing intervals of nivolumab: model-based simulations in unselected cancer patients
Alicja Puszkiel, Guillaume Bianconi, Blaise Pasquiers, et al.
Cancers
|
November 27, 2019
Is there an Exposure-Response Relationship for Nivolumab in Real-World NSCLC Patients?
Audrey Bellesoeur, Edouard Ollier, Marie Allard, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 17, 2018
<i>TP53, STK11</i>, and <i>EGFR</i> Mutations Predict Tumor Immune Profile and the Response to Anti-PD-1 in Lung Adenocarcinoma
Jérôme Biton, Audrey Mansuet-Lupo, Nicolas Pécuchet, et al.
The Lancet. Oncology
|
November 28, 2018
Efficacy and safety of regorafenib in adult patients with metastatic osteosarcoma: a non-comparative, randomised, double-blind, placebo-controlled, phase 2 study
Florence Duffaud, Olivier Mir, Pascaline Boudou-Rouquette, et al.
Cancers
|
February 23, 2020
Predictive Value of Soluble PD-1, PD-L1, VEGFA, CD40 Ligand and CD44 for Nivolumab Therapy in Advanced Non-Small Cell Lung Cancer: A Case-Control Study
Manuela Tiako Meyo, Anne Jouinot, Etienne Giroux-Leprieur, et al.
Ebiomedicine
|
October 23, 2021
Development and validation of a host-dependent, PDL1-independent, biomarker to predict 6-month progression-free survival in metastatic non-small cell lung cancer (mNSCLC) patients treated with anti-PD1 immune checkpoint inhibitors (ICI) in the CERTIM Cohort: The ELY study
Pascaline Boudou-Rouquette, Jennifer Arrondeau, Claire Gervais, et al.
International Journal of Cancer
|
September 25, 2021
Treatment of 120 adult osteosarcoma patients with metachronous and synchronous metastases: A retrospective series of the French Sarcoma Group
Elise Lavit, Mihaela Aldea, Sophie Piperno-Neumann, et al.
International Journal of Cancer
|
October 6, 2021
Rare bone sarcomas: A retrospective analysis of 145 adult patients from the French Sarcoma Group
Pascaline Boudou-Rouquette, Elodie Martin, Emmanuelle Kempf, et al.
The New England Journal of Medicine
|
September 4, 2024
Doxorubicin-Trabectedin with Trabectedin Maintenance in Leiomyosarcoma
Patricia Pautier, Antoine Italiano, Sophie Piperno-Neumann, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 8, 2025
Droplet Digital PCR Assay for Detection and Monitoring of Universally Methylated Circulating Tumor DNA in Sarcoma Patients
Elisabeth Ashton, Valérie Taly, Camille Tlemsani, et al.
Page
of 13
Search research articles
Search
Showing results (91-100 of 122) with videos related to
Sort By:
Page
of 13
British Journal of Cancer
|
March 27, 2024
Extending the dosing intervals of nivolumab: model-based simulations in unselected cancer patients
Alicja Puszkiel, Guillaume Bianconi, Blaise Pasquiers, et al.
Cancers
|
November 27, 2019
Is there an Exposure-Response Relationship for Nivolumab in Real-World NSCLC Patients?
Audrey Bellesoeur, Edouard Ollier, Marie Allard, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 17, 2018
<i>TP53, STK11</i>, and <i>EGFR</i> Mutations Predict Tumor Immune Profile and the Response to Anti-PD-1 in Lung Adenocarcinoma
Jérôme Biton, Audrey Mansuet-Lupo, Nicolas Pécuchet, et al.
The Lancet. Oncology
|
November 28, 2018
Efficacy and safety of regorafenib in adult patients with metastatic osteosarcoma: a non-comparative, randomised, double-blind, placebo-controlled, phase 2 study
Florence Duffaud, Olivier Mir, Pascaline Boudou-Rouquette, et al.
Cancers
|
February 23, 2020
Predictive Value of Soluble PD-1, PD-L1, VEGFA, CD40 Ligand and CD44 for Nivolumab Therapy in Advanced Non-Small Cell Lung Cancer: A Case-Control Study
Manuela Tiako Meyo, Anne Jouinot, Etienne Giroux-Leprieur, et al.
Ebiomedicine
|
October 23, 2021
Development and validation of a host-dependent, PDL1-independent, biomarker to predict 6-month progression-free survival in metastatic non-small cell lung cancer (mNSCLC) patients treated with anti-PD1 immune checkpoint inhibitors (ICI) in the CERTIM Cohort: The ELY study
Pascaline Boudou-Rouquette, Jennifer Arrondeau, Claire Gervais, et al.
International Journal of Cancer
|
September 25, 2021
Treatment of 120 adult osteosarcoma patients with metachronous and synchronous metastases: A retrospective series of the French Sarcoma Group
Elise Lavit, Mihaela Aldea, Sophie Piperno-Neumann, et al.
International Journal of Cancer
|
October 6, 2021
Rare bone sarcomas: A retrospective analysis of 145 adult patients from the French Sarcoma Group
Pascaline Boudou-Rouquette, Elodie Martin, Emmanuelle Kempf, et al.
The New England Journal of Medicine
|
September 4, 2024
Doxorubicin-Trabectedin with Trabectedin Maintenance in Leiomyosarcoma
Patricia Pautier, Antoine Italiano, Sophie Piperno-Neumann, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 8, 2025
Droplet Digital PCR Assay for Detection and Monitoring of Universally Methylated Circulating Tumor DNA in Sarcoma Patients
Elisabeth Ashton, Valérie Taly, Camille Tlemsani, et al.
Page
of 13